298 related articles for article (PubMed ID: 16225492)
1. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Grimstad T; Berstad A; Berge RK; Hausken T
Aliment Pharmacol Ther; 2005 Nov; 22(9):831-8. PubMed ID: 16225492
[TBL] [Abstract][Full Text] [Related]
2. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.
Erichsen K; Ulvik RJ; Nysaeter G; Johansen J; Ostborg J; Berstad A; Berge RK; Hausken T
Scand J Gastroenterol; 2005 Sep; 40(9):1058-65. PubMed ID: 16165718
[TBL] [Abstract][Full Text] [Related]
3. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose.
Jacobs P; Johnson G; Wood L
J Med; 1984; 15(5-6):367-77. PubMed ID: 6599114
[TBL] [Abstract][Full Text] [Related]
4. Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats.
Toblli JE; Cao G; Angerosa M
Drug Des Devel Ther; 2015; 9():2585-97. PubMed ID: 26005335
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
Swarnalatha G; Ram R; Neela P; Naidu MU; Dakshina Murty KV
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
7. Ferrous sulfate (Fe2+) had a faster effect than did ferric polymaltose (Fe3+) on increased oxidant status in children with iron-deficiency anemia.
Aycicek A; Koc A; Oymak Y; Selek S; Kaya C; Guzel B
J Pediatr Hematol Oncol; 2014 Jan; 36(1):57-61. PubMed ID: 23743961
[TBL] [Abstract][Full Text] [Related]
8. Iron hydroxide polymaltose: iatrogenic cause of persistent iron deficiency anaemia despite continuous oral iron therapy.
Mehta BC
J Assoc Physicians India; 2002 Feb; 50():279-80. PubMed ID: 12038667
[No Abstract] [Full Text] [Related]
9. Evaluation of efficacy and safety of iron polymaltose complex and folic acid (Mumfer) vs iron formulation (ferrous fumarate) in female patients with anaemia.
Reddy PS; Adsul BB; Gandewar K; Korde KM; Desai A
J Indian Med Assoc; 2001 Mar; 99(3):154-5. PubMed ID: 11478761
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial.
de Silva AD; Tsironi E; Feakins RM; Rampton DS
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1097-105. PubMed ID: 16305723
[TBL] [Abstract][Full Text] [Related]
11. Intravenous versus oral iron therapy for postpartum anaemia.
Bhandal N; Russell R
BJOG; 2006 Nov; 113(11):1248-52. PubMed ID: 17004982
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress markers and antioxidant status after oral iron supplementation to very low birth weight infants.
Braekke K; Bechensteen AG; Halvorsen BL; Blomhoff R; Haaland K; Staff AC
J Pediatr; 2007 Jul; 151(1):23-8. PubMed ID: 17586185
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study.
Ortiz R; Toblli JE; Romero JD; Monterrosa B; Frer C; Macagno E; Breymann C
J Matern Fetal Neonatal Med; 2011 Nov; 24(11):1347-52. PubMed ID: 21859366
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of iron from oral ferric polymaltose in humans.
Nielsen P; Gabbe EE; Fischer R; Heinrich HC
Arzneimittelforschung; 1994 Jun; 44(6):743-8. PubMed ID: 8053973
[TBL] [Abstract][Full Text] [Related]
16. Ferrous sulfate versus iron polymaltose complex for treatment of iron deficiency anemia in children.
Bopche AV; Dwivedi R; Mishra R; Patel GS
Indian Pediatr; 2009 Oct; 46(10):883-5. PubMed ID: 19430060
[TBL] [Abstract][Full Text] [Related]
17. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
18. Equivalent effects on fecal reactive oxygen species generation with oral supplementation of three iron compounds: ferrous sulfate, sodium iron EDTA and iron polymaltose.
Orozco MN; Arriaga C; Solomons NW; Schümann K
Ann Nutr Metab; 2012; 60(2):108-14. PubMed ID: 22414964
[TBL] [Abstract][Full Text] [Related]
19. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats.
Geisser P; Müller A
Arzneimittelforschung; 1984; 34(11):1560-9. PubMed ID: 6543131
[TBL] [Abstract][Full Text] [Related]
20. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
